Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10101791 | 0.93 | MAPT (0.30) | MAPT | |
| SCHEMBL10101792 | 0.91 | MAPT (0.34) | GAAMAPTL3MBTL1RAB9A | |
| SCHEMBL10101795 | 0.84 | TUBB4A (0.30) | — | |
| SCHEMBL10101784 | 0.82 | MAOA (0.45) | GAAMAPTL3MBTL1RAB9AMAOA | |
| SCHEMBL10102267 | 0.79 | L3MBTL1 (0.42) | GAAMAPTL3MBTL1RAB9AMAOA | |
| SCHEMBL10102240 | 0.75 | MAPT (0.43) | GAAMAPTRAB9A | |
| SCHEMBL10101786 | 0.74 | MAOB (0.39) | GAAMAPTL3MBTL1RAB9AMAOA | |
| SCHEMBL10101787 | 0.73 | MAOA (0.42) | GAAMAPTL3MBTL1RAB9AMAOA | |
| SCHEMBL10102273 | 0.71 | ALDH1A1 (0.38) | MAPTL3MBTL1RAB9A | |
| SCHEMBL10102274 | 0.71 | L3MBTL1 (0.40) | GAAMAPTL3MBTL1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536157-B2 | Non-steroidal compounds | THE UNIVERSITY OF MELBOURNE (AU) | 2013-09-17 | — | — | US | disclosed |
| US-20120046255-A1 | NON-STEROIDAL COMPOUNDS | THE UNIVERSITY OF MELBOURNE of ROYAL PARADE PARKVILLE (AU) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046255-A1 | NON-STEROIDAL COMPOUNDS | PTGES2, PTGES, PTGES3 | GAA 2110/4885MAPT 2433/4885L3MBTL1 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.